Excipient World Conference & Expo

About this event

Excipient World Conference & Expo — Global Excipient & Formulation Buyers Research Brief

Quick Event Snapshot (What it is and why it matters)

Excipient World Conference & Expo is a specialized industry conference and exhibition focused on pharmaceutical excipients—the inactive ingredients used to formulate medicines—and the practical formulation, quality, regulatory, and supply-chain topics that directly influence drug product development and commercialization. The event typically brings together excipient manufacturers, ingredient suppliers, formulation and development scientists, quality/regulatory professionals, and decision-makers from pharmaceutical and biopharmaceutical companies. Because excipients are foundational to stability, bioavailability, patient safety, manufacturability, and compliance, buyer attendance is usually concentrated among roles that influence: ingredient selection, supplier qualification, regulatory strategy, technical transfer, scale-up, and supply reliability.

Assumptions & Notes on Data

Excipient World can vary year-to-year by city, organizer program, and exhibitor roster size. The sections below provide a buyer-focused research analysis designed for attendee/buyer discovery. Where exact attendance numbers are not confirmed inside this request, we provide industry-reasonable estimates and buyer-density logic used for outreach prioritization. If we share the event’s specific edition (city/date/year), we can tighten geographic origin estimates and refine buyer categories.

---

1️⃣ Who attends (BUYERS / ATTENDEES)

This is a high-intent B2B technical-and-commercial audience rather than a general pharma crowd. The “buyers” (in the sense of people who influence or purchase excipients and excipient-related services) tend to attend in roles that own formulation outcomes, quality compliance, and sourcing decisions.

A. Primary buyer/decision-maker attendee groups

• Pharmaceutical Product Development / Formulation Directors & Managers (need functional performance, compatibility, stability, and manufacturability)
• Quality Assurance & Quality Control leaders (excipient compliance, testing strategy, documentation packages, GMP alignment)
• Regulatory Affairs professionals (regulatory filings, change control strategy, regulatory risk management)
• Procurement / Strategic Sourcing (supplier qualification workflows, contract negotiations, supply assurance)
• Supply Chain / Technical Operations leaders (lead times, continuity of supply, contingency planning)
• R&D Scientists & Technical Specialists (directly evaluate excipients, perform trials, and shape recommendations)
• Contract Development & Manufacturing Organization (CDMO/CRO) formulation teams (excipient selection guidance for client programs)

B. Secondary attendees (still valuable for business outcomes)

• Technical marketing teams from excipient suppliers (they influence which excipients get piloted and chosen)
• Audit/compliance teams supporting supplier qualification
• Industry consultants and excipient-related service providers (testing, regulatory consulting, analytics)
• Packaging and drug product manufacturing specialists who collaborate with excipient choices

Buyer-density logic: Even if the total headcount isn’t huge compared to mega pharma events, the attendance is typically high in technical decision influence, making it strong for targeted outreach—especially for excipient manufacturers, distributors, and excipient-related solution providers.

2️⃣ Where the show is happening + attendee geographic origin

Excipient World Conference & Expo is international in scope and typically includes attendees from: North America, Europe, and Asia-Pacific, with additional representation from Middle East/Latin America depending on the host location and exhibitor footprint.

Common geographic origin patterns (typical for excipient procurement ecosystems)

• Host-region dominance: The largest share of walk-ins and exhibitor interactions usually come from the host country and nearby countries (within the same regulatory and commercial ecosystem).
• North America: Strong participation from US, Canada, and Mexico-based pharma, biopharma, and service providers.
• Europe: Heavy representation from UK, Germany, France, Switzerland, Netherlands, and Nordics due to excipient regulatory rigor and widespread manufacturing footprint.
• Asia-Pacific: Increasing attendance from excipient manufacturing hubs and formulation/manufacturing organizations across India, China, Singapore, and Japan (often driven by supplier qualification and technical capability discussions).
• International supplier & distributor networks: Exhibitors bring global account teams, which increases international buyer coverage even when the show is hosted in a single region.

Best practical targeting takeaway: We recommend prioritizing buyer profiles whose company headquarters or R&D/Manufacturing sites are located where excipient supply chains are actively qualified—typically EU + US + major APAC pharma corridors.

3️⃣ Audience reach (Local / National / Global)

Global reach, but buyer intent is concentrated. This event is best categorized as: Global with regional clustering (because regulatory and commercial teams often prefer traveling to highly relevant niche industry conferences where supplier qualification discussions occur efficiently).

• Local component: Highest concentration of attendees for the host country and neighboring regions.
• National component: Strong followership from pharma clusters within the host region (major pharma hubs plus technical universities tied to formulation R&D).
• Global component: Excipient manufacturers and pharmaceutical companies attend from multiple continents; the expo hall becomes a cross-regional supplier qualification meeting point.

4️⃣ Sample buyer company names (BUYERS ONLY) + Websites

Below are buyer-oriented targets—pharmaceutical, biopharma, and drug development/manufacturing organizations that are plausible to purchase excipients or influence excipient selection via formulation/quality/regulatory/procurement processes. We would refine these further once you share the client product details and target excipient category (e.g., binders, fillers, disintegrants, sustained-release polymers, solubilizers, coatings, surfactants).

Priority	Company	Website	Best Title to Target	Why This is a Good Buyer Fit
1	Pfizer	pfizer.com	Head of Pharmaceutical Development / Formulation Director / Technical Project Lead	Major portfolio with multiple dosage forms; excipient performance drives stability, bioavailability, and manufacturability across programs.
2	Roche	roche.com	Director of Pharmaceutical Sciences / Formulation & Drug Product Development Manager	Strong small-molecule and biologics ecosystem; excipients and formulation strategy are central to product transfer and quality consistency.
3	Novartis	novartis.com	Global Head of Drug Product Development / Formulation Science Manager	High R&D throughput and manufacturing complexity; supplier qualification and technical feasibility depend on excipient selection.
4	Sanofi	sanofi.com	VP / Director of Pharmaceutical Development / Formulation & Product Quality Leader	Broad dosage-form needs; excipient specifications and regulatory documentation are critical across lifecycle management.
5	GSK	gsk.com	Head of Formulation Development / Quality & Regulatory Interface Lead	Focused on rigorous quality and compliance; excipients influence change control and regulatory submissions.
6	Johnson & Johnson (Janssen)	janssen.com	Director, Drug Product Development / Formulation Project Manager	Large development pipeline; excipient selection and tech transfer directly support scalable manufacturing outcomes.
7	Merck (MSD)	merck.com	Head of Pharmaceutical Development / Drug Product Formulation Manager	Global manufacturing footprint increases need for consistent excipient supply, comparability, and regulatory readiness.
8	AbbVie	abbvie.com	Senior Director, Product Development / Formulation & Process Development	Chronic and complex dosage forms often require carefully selected excipients for patient experience and stability.
9	Bayer	bayer.com	Director, Drug Product Development / Pharmaceutical Technology Lead	Multi-formulation programs; excipient sourcing and quality documentation are key for sustained lifecycle.
10	AstraZeneca	astrazeneca.com	Principal Scientist / Formulation Development Lead	Strong emphasis on development-to-commercial transfer; excipients are central to performance and compliance across regions.
11	Teva Pharmaceuticals	teva.com	Head of Product Development / Formulation & Pharm Sciences	Large portfolio including generics; excipient selection impacts bioequivalence, stability, and regulatory submissions.
12	Amgen	amgen.com	Director, Drug Product Development / Technical Operations Liaison	Complex dosage forms require careful excipient choices and strict quality/regulatory controls.
13	Gilead Sciences	gilead.com	Director, Formulation Development / Quality Strategy Lead	Multiple dosage formats across therapeutic areas; excipients affect stability and manufacturability.
14	Biogen	biogen.com	Head of Pharmaceutical Development / Drug Product Quality Lead	Quality-driven product development where excipient compliance and documentation are critical.
15	Takeda	takeda.com	Director, Pharmaceutical Development / Formulation & Product Quality	Global manufacturing and lifecycle needs make supplier quality, documentation, and stability key.
16	CDMO: Catalent	catalent.com	Vice President, Formulation & Drug Product Development	CDMO environment: excipient recommendations and qualification are core to client drug product success.
17	CDMO: Lonza	lonza.com	Director, Drug Product Development / Quality Assurance Strategy	Large CDMO footprint; formulation and scale-up require robust excipient strategy and compliance alignment.
18	CRO/CDMO: Thermo Fisher Scientific (CDMO/CRO segments)	thermofisher.com	Director, Pharmaceutical Development Services / Technical Transfer Manager	Technical services teams advise on formulation and manufacturing; excipient choices are frequent project inputs.

Top buyer priorities to start outreach with (for maximum relevance): Pfizer, Roche, Novartis, Sanofi, GSK, AstraZeneca, Teva, and major CDMOs like Catalent and Lonza. These account for both direct pharmaceutical buying influence and formulation engineering decision-making.

5️⃣ Job profiles, industries & event type

A. Best job profiles to target

• Director / Head of Pharmaceutical Development (sets formulation direction and key supplier inputs)
• Formulation Science Manager / Drug Product Development Manager (evaluates excipient options)
• Product Development Project Lead / Technical Project Manager (drives cross-functional timelines and supplier involvement)
• Quality Assurance Director / QA Compliance Lead (approves supplier qualification approach)
• Quality Control Manager (supports testing methods and specifications)
• Regulatory Affairs Director / Regulatory Strategy Lead (supports change control, CMC documentation)
• Procurement / Strategic Sourcing Manager (Pharma) (negotiates contracts and supply continuity)
• Supply Chain / Global Logistics Lead (Pharma Materials) (lead times, continuity of supply)
• Supplier Quality / Vendor Qualification Manager (audit outcomes and ongoing compliance)
• CMC Manager (ensures excipient documentation supports filings)
• R&D Scientist (Drug Substance/Product) (technical selection and method development)
• CDMO Technical Operations / Tech Transfer Manager (ensures excipient readiness for scale-up)

B. Industries most represented (in our targeting logic)

• Pharmaceuticals
• Biotechnology
• Medical Devices (sometimes for drug-device combination contexts, depending on exhibitors)
• Hospital & Health Care (less common as a buyer core, but may appear via clinical formulation support)
• Outsourcing/Offshoring (major for CDMO/CRO attendees)
• Research (academic/industry research teams in specific sessions)
• Chemicals (excipient manufacturers and specialty ingredients)
• Events Services / Industry Associations (for conference and sponsor ecosystem)

C. Event type classification

• B2B Specialty Conference + Expo
• Pharma CMC / Formulation / Regulatory & Quality focused program
• Exhibitor-led technical engagement (spec sheets, use cases, compliance packs, technical demonstrations)

6️⃣ Estimated attendance (expected total footfall)

As a specialized niche event, the attendee count is generally smaller than general pharma congresses but with a higher buyer relevance ratio. A typical scenario for excipient-focused conferences can range from a few hundred to over a few thousand attendees depending on the edition and expo scale.

Working estimate for planning outreach: ~1,000 to 3,000 total attendees (conference + expo) with buyer-rich density in formulation, quality, regulatory, and sourcing functions.

Buyer-density note: Even if overall headcount is moderate, booth meetings and technical session participation frequently include senior technical and compliance decision-makers. That makes it strong for high-quality lead generation rather than broad mass outreach.

7️⃣ Key focus areas & buyer engagement

A. Key focus areas that attract and retain buyer attention

• Excipient functionality by dosage form (solid oral, injectables, modified release, inhalation, topical, etc.)
• Regulatory & quality updates (GMP expectations, documentation standards, regulatory compliance expectations)
• CMC and change control readiness (managing sourcing changes, equivalency, comparability)
• Stability and performance (shelf-life impact, moisture uptake, compatibility)
• Manufacturability and process scale-up (mixing, compression, granulation, coating, drying impacts)
• Sustainability and supply resilience (sustainable sourcing, multi-source strategies, continuity planning)
• Technical transfer and qualification (validation approach for new excipient introductions)
• Analytical support and testing (specifications, characterization methods, impurity management)

B. Most effective buyer engagement angles for outreach

• “Technical fit” messaging: excipient performance and compatibility outcomes for specific dosage forms
• “Regulatory-ready documentation” messaging: CoA/data packages, change control support, compliance evidence
• “Quality assurance alignment” messaging: supplier qualification support, audit readiness, traceability
• “Supply continuity” messaging: continuity planning, lead-time clarity, contingency options
• “Manufacturing collaboration” messaging: scale-up support, process parameter considerations

8️⃣ Client-product fit: request for your website to identify best-fit buyers

We can provide a best-fit buyer shortlist tailored to your exact offering, but we need to review your product and claims. Please share the client website URL (or product page links).

Once we review it, we will map your solution to attendee buying roles and industry clusters. For example, buyer priority changes depending on whether your client sells:

• Excipient products themselves (direct procurement + formulation + quality buyers)
• Excipient distribution / sourcing services (strategic sourcing, supplier quality, supply chain continuity)
• Testing, analytics, or compliance services (QA/QC, regulatory strategy, CMC)
• Specialty formulation or application support (formulation science leads, technical transfer teams)

After you share the website, we will return: the best buyer segments, exact job-title targets, and an expanded 15–20 buyer sample list aligned to your product category.

9️⃣ Suggested industry targeting (from your industry list logic)

Based on the conference theme and typical exhibitor/buyer composition, the most relevant industry targeting (using the industry categories you listed) usually includes:

• Pharmaceuticals
• Chemicals
• Biotechnology
• Medical Devices (selectively, depending on exhibitors/program focus)
• Outsourcing/Offshoring (for CDMO/CRO and service providers)
• Research (for technical and application research teams)
• Professional Training & Coaching (occasionally for compliance/technical training—typically lower priority)
• Events Services (usually not a buyer fit unless the product is event/industry tooling)

---

Recommended Next Step (to finalize the “best buyers” shortlist)

Please paste the client website (and if possible: 1–2 lines on the product category, target excipient type, and primary customer type). Then we will produce a refined buyer list prioritizing the most relevant job profiles and companies for that specific offering.

If you want, we can also tailor this brief to the exact edition

If you share the event edition (city, dates, year), we will refine: attendee geographic origin, expected regional buying concentration, and the most likely exhibitor-to-buyer overlap for that location.